BST labeling not resolved
WASHINGTON - A joint meeting of two FDA advisory committees adjourned Friday after two days of hearings without voting to recommend whether the agency should require special labeling or other consumer notification for products derived from cows receiving recombinant bovine somatotropin. The deliberations underscored significant obstacles to implementing labeling requirements for BST